We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 03, 2020

Bortezomib, Thalidomide, and Dexamethasone Followed by Double Auto-HSCT for Newly Diagnosed Multiple Myeloma

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Bortezomib, Thalidomide, and Dexamethasone Followed by Double Autologous Haematopoietic Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (GIMEMA-MMY-3006): Long-Term Follow-Up Analysis of a Randomised Phase 3, Open-Label Study
Lancet Haematol 2020 Dec 01;7(12)e861-e873, P Tacchetti, L Pantani, F Patriarca, MT Petrucci, E Zamagni, L Dozza, M Galli, F Di Raimondo, C Crippa, M Boccadoro, S Barbato, P Tosi, F Narni, V Montefusco, N Testoni, A Spadano, C Terragna, N Pescosta, G Marzocchi, C Cellini, P Galieni, S Ronconi, M Gobbi, L Catalano, A Lazzaro, G De Sabbata, C Cangialosi, F Ciambelli, P Musto, F Elice, M Cavo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading